Latest News

The latest in our partnerships, collaborations, company updates, and milestones.

Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery

Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023

Medinvest Oncology Investor Conference
Inimmune to Present at the Medinvest Oncology Conference on INI-4001
World Vaccine Congress
Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st
Medinvest Oncology Investor Conference
Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001
World Vaccine Congress (West Coast)
Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs